✦ LIBER ✦

High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study

✍ Scribed by Luiz Caetano da Silva; Leda Bassit; Suzane Kioko Ono-Nita; João Renato Rebello Pinho; Ana Nishiya; Carmen Lucia Madruga; Flair José Carrilho

Publisher: Springer Japan
Year: 2002
Tongue: English
Weight: 60 KB
Volume: 37
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s005350200119

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined treatment with interferon alpha

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

✍ R. Schvarcz; Z. B. Yun; A. Sönnerborg; O. Weiland 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 2 views

Ten patients with chronic hepatitis C, six of whom had not responded and four of whom had responded in a non-sustained fashion to interferon-alpha treatment alone, were given interferon alpha-2b and ribavirin in combination during 24 weeks. Interferon alpha-2b was given subcutaneously, at a dose of

Neutralizing antibodies to interferon-α

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*)

✍ Philippe Halfon; Sophie Pérusat; Marc Bourlière; Jean-Pierre Bronowicki; Pascale 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)‐interferon (IFN)‐α‐2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN‐α‐2a. The aim of this study was to assess neutralizing antibodies to IFN‐α‐2a and IFN levels in non‐

Mutations in the interferon sensitivity

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

✍ Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yas 📂 Article 📅 2010 🏛 Springer Japan 🌐 English ⚖ 266 KB

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated

Immunological predictors of different re

Immunological predictors of different responses to combination therapy with interferon α and ribavirin in patients with chronic hepatitis C

✍ Ravdan Amaraa; Helena Mareckova; Petr Urbanek; Terezie Fucikova 📂 Article 📅 2003 🏛 Springer Japan 🌐 English ⚖ 215 KB

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may